The sleep apnea device developer has raised more than $71m since 2009 from investors including Medtronic and Johnson & Johnson Development Corporation.

The size of the suit represents the amount Walgreens had invested in the beleaguered blood testing company, once valued at $9bn.

Six universities have joined forces with Unilever and GE Healthcare to launch a $13.2m collaboration network aimed at businesses in Ireland and Wales.

Blue Cross Blue Shield of Massachusetts, Heitkamp & Thumann and Guardian Life Insurance have contributed to the respiratory monitor device developer's series A round.

Novo Seeds led a $17.1m round for the medical device developer, which had been backed by Medtronic at series A stage.

Mike Chuisano will remain in his role through January 1, 2017, as he transitions venture investment portfolio responsibilities to his successor.

Asarina Pharma has raised $7.7m from investors including Ergomed, which will help it with phase 2b trials of its premenstrual dysphoric disorder treatment.

Existing investor Boehringer Ingelheim Venture Fund took part in a round that will help advance NBE's lead antibody-drug conjugate cancer treatment in clinical trials.